Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Current Assets (2016 - 2025)

Anaptysbio (ANAB) has disclosed Current Assets for 10 consecutive years, with $350.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Current Assets fell 18.9% year-over-year to $350.2 million, compared with a TTM value of $350.2 million through Dec 2025, down 18.9%, and an annual FY2025 reading of $350.2 million, down 18.9% over the prior year.
  • Current Assets was $350.2 million for Q4 2025 at Anaptysbio, up from $330.6 million in the prior quarter.
  • Across five years, Current Assets topped out at $553.9 million in Q4 2021 and bottomed at $291.9 million in Q2 2025.
  • Average Current Assets over 5 years is $412.8 million, with a median of $417.4 million recorded in 2023.
  • The sharpest move saw Current Assets surged 39.67% in 2021, then fell 26.31% in 2025.
  • Year by year, Current Assets stood at $553.9 million in 2021, then fell by 19.26% to $447.2 million in 2022, then dropped by 9.03% to $406.8 million in 2023, then rose by 6.16% to $431.9 million in 2024, then fell by 18.9% to $350.2 million in 2025.
  • Business Quant data shows Current Assets for ANAB at $350.2 million in Q4 2025, $330.6 million in Q3 2025, and $291.9 million in Q2 2025.